<p>在保誠集團決定收購巴蒂 AXA 人壽保險控股權後，ICICI 保誠人壽保險的急劇拋售重新點燃了投資者對該保險公司增長軌跡的擔憂，市場專家告訴 Moneycontrol，關於大宗交易的潛在壓力加劇了對以銀行保險為主導的增長放緩和持續估值下調的擔憂。</p>
<p>5 月 18 日拋售的直接觸發因素是保誠集團擬收購巴蒂人壽保險 75% 的股份，這將要求這家英國保險公司根據印度保險法規將其在 ICICI 保誠人壽的約 22% 的持股比例削減至 10% 以下。預計近 12% 的股份出售——估計約為 920 億印度盧比——加劇了對持續拋售壓力和進一步估值壓縮的擔憂，而此時該保險公司已經面臨相對較弱的增長，無法與行業同行相比。</p>
<p>儘管大多數券商並未看到任何直接的運營影響，但這一舉動加劇了市場上已有的爭論：ICICI 保誠人壽向較慢但更高質量增長的轉型是否在結構上限制了其估值倍數。</p>
<p>Bernstein 採取了最謹慎的態度，認為保誠可能實際上是在 “放棄” 通過其在 ICICI 保誠人壽的少數股權創造有意義的價值，而是轉向在巴蒂人壽的控股地位，以便直接推動戰略和分銷。該券商指出，該股票 “便宜且可能會變得更便宜”，質疑誰會在不要求折扣的情況下吸收這筆大額股份出售。</p>
<p>Axis Capital 也對市場份額損失、較弱的持續性趨勢和高昂的費用比率表示擔憂，同時維持 “增持” 評級，目標價為 625 印度盧比。該券商表示，儘管盈利指標健康且保護產品的吸引力增強，但增長仍然温和。</p>
<p>相比之下，摩根士丹利維持 “增持” 評級，目標價為 670 印度盧比，認為保誠交易並未改變 ICICI 保誠人壽的核心運營基本面。野村證券維持 “買入” 評級，目標價為 680 印度盧比，指出在最新拋售之前，該股票已經明顯跑輸大盤和同行。</p>
<p>影響投資者情緒的一個核心問題是，在 Sandeep Bakhshi 接任 ICICI 銀行首席執行官後，該保險公司自 2018 年以來逐漸放棄了激進的以銀行保險為主導的增長。在更嚴格的治理和對誤售的嚴格控制下，ICICI 保誠對 ICICI 銀行渠道的依賴大幅減少，銀行貢獻從歷史上的約 70-75% 降至約 26-30% 的年保費等值。</p>
<p>雖然這一轉型提高了產品質量，分散了分銷渠道並增強了利潤率，但分析師表示，這也限制了激進的銷量增長，迫使投資者重新評估該公司，更像是一個穩定的盈利複合體，而不是一個高增長的保險品牌。</p>
<p>最近的財報強化了這種看法。管理層未對 2027 財年的激進增長指引做出承諾，而是強調了以保護為主導的增長、利潤率擴張和在動盪的宏觀背景下的成本效率。儘管年保費等值增長仍然温和，但由於產品組合的改善，新業務利潤率大幅提升。</p>
<p>結果是，該股票現在的估值倍數在大型上市保險公司中處於最低水平之一。ICICI 保誠人壽的交易價格約為 2027 財年內嵌價值的 1.3-1.5 倍，低於 HDFC 人壽保險和 SBI 人壽保險等同行。</p>
<p>對於看漲者來説，這一折扣加上強勁的償付能力、改善的保護組合和穩定的盈利能力為估值提供了潛在的底線。對於看跌者來説，保誠的股份出售壓力、較慢的增長特徵和低迷的分銷勢頭引發了對近期是否可能實現有意義的重新評級的質疑。</p>

保誠集團

英國保誠

英國保誠集團

<p>ICICI 保誠人壽保險的股票在保誠集團收購巴蒂 AXA 人壽保險控股權後遭遇拋售，市場對增長和潛在估值壓縮表示擔憂。對 ICICI 保誠近 12% 股份的出售被擔心會增加賣壓。儘管一些券商維持積極評級，但其他券商對市場份額損失和增長放緩表示謹慎。該保險公司從激進的銀行保險增長轉變，導致其估值被重新評估，當前的交易倍數低於同行</p>

<p>The sharp selloff in ICICI Prudential Life Insurance following Prudential plc’s decision to acquire a controlling stake in Bharti AXA Life Insurance has reignited investor concerns around the insurer’s growth trajectory, with fears of a large block-deal overhang adding to worries over bancassurance-led growth slowdown and ongoing valuation de-rating, market experts told Moneycontrol.</p>
<div class="lb-trans"><p>在保誠集團決定收購巴蒂 AXA 人壽保險控股權後，ICICI 保誠人壽保險的急劇拋售重新點燃了投資者對該保險公司增長軌跡的擔憂，市場專家告訴 Moneycontrol，關於大宗交易的潛在壓力加劇了對以銀行保險為主導的增長放緩和持續估值下調的擔憂。</p>
</div><p>The immediate trigger for the May 18 selloff was Prudential Plc’s proposed acquisition of a 75% stake in Bharti Life Insurance, which would require the UK insurer to cut its roughly 22% holding in ICICI Prudential Life to below 10% under Indian insurance regulations. The prospect of a nearly 12% stake sale — estimated at around Rs 9,200 crore — has heightened concerns over sustained selling pressure and further valuation compression at a time when the insurer is already grappling with relatively weaker growth versus industry peers.</p>
<div class="lb-trans"><p>5 月 18 日拋售的直接觸發因素是保誠集團擬收購巴蒂人壽保險 75% 的股份，這將要求這家英國保險公司根據印度保險法規將其在 ICICI 保誠人壽的約 22% 的持股比例削減至 10% 以下。預計近 12% 的股份出售——估計約為 920 億印度盧比——加劇了對持續拋售壓力和進一步估值壓縮的擔憂，而此時該保險公司已經面臨相對較弱的增長，無法與行業同行相比。</p>
</div><p>While most brokerages do not see any immediate operational impact, the move has amplified an existing market debate: whether ICICI Prudential Life’s transition toward slower but higher-quality growth structurally caps its valuation multiples.</p>
<div class="lb-trans"><p>儘管大多數券商並未看到任何直接的運營影響，但這一舉動加劇了市場上已有的爭論：ICICI 保誠人壽向較慢但更高質量增長的轉型是否在結構上限制了其估值倍數。</p>
</div><p>Bernstein struck the most cautious tone, arguing Prudential may effectively be “throwing in the towel” on meaningful value creation through its minority holding in ICICI Prudential Life and instead pivoting toward a controlling position in Bharti Life where it can drive strategy and distribution directly. The brokerage noted that the stock “is cheap and will likely get cheaper,” questioning who would absorb the large stake sale without demanding a discount.</p>
<div class="lb-trans"><p>Bernstein 採取了最謹慎的態度，認為保誠可能實際上是在 “放棄” 通過其在 ICICI 保誠人壽的少數股權創造有意義的價值，而是轉向在巴蒂人壽的控股地位，以便直接推動戰略和分銷。該券商指出，該股票 “便宜且可能會變得更便宜”，質疑誰會在不要求折扣的情況下吸收這筆大額股份出售。</p>
</div><p>Axis Capital also flagged concerns around market-share losses, weaker persistency trends and elevated expense ratios, while maintaining an “Add” rating with a target price of Rs 625. The brokerage said growth remains modest despite healthy profitability metrics and stronger traction in protection products.</p>
<div class="lb-trans"><p>Axis Capital 也對市場份額損失、較弱的持續性趨勢和高昂的費用比率表示擔憂，同時維持 “增持” 評級，目標價為 625 印度盧比。該券商表示，儘管盈利指標健康且保護產品的吸引力增強，但增長仍然温和。</p>
</div><p>In contrast, Morgan Stanley maintained an “Overweight” rating with a Rs 670 target price, arguing the Prudential transaction does not alter ICICI Prudential Life’s core operating fundamentals. Nomura retained its “Buy” rating with a Rs 680 target price, pointing out that the stock had already materially underperformed both the broader market and peers before the latest selloff.</p>
<div class="lb-trans"><p>相比之下，摩根士丹利維持 “增持” 評級，目標價為 670 印度盧比，認為保誠交易並未改變 ICICI 保誠人壽的核心運營基本面。野村證券維持 “買入” 評級，目標價為 680 印度盧比，指出在最新拋售之前，該股票已經明顯跑輸大盤和同行。</p>
</div><p>A central issue weighing on investor sentiment is the insurer’s post-2018 shift away from aggressive bancassurance-led growth after Sandeep Bakhshi took over as CEO of ICICI Bank. Under tighter governance and stricter controls on mis-selling, ICICI Prudential’s dependence on the ICICI Bank channel sharply reduced, bringing down banca contribution from roughly 70-75% historically to about 26-30% of annual premium equivalent.</p>
<div class="lb-trans"><p>影響投資者情緒的一個核心問題是，在 Sandeep Bakhshi 接任 ICICI 銀行首席執行官後，該保險公司自 2018 年以來逐漸放棄了激進的以銀行保險為主導的增長。在更嚴格的治理和對誤售的嚴格控制下，ICICI 保誠對 ICICI 銀行渠道的依賴大幅減少，銀行貢獻從歷史上的約 70-75% 降至約 26-30% 的年保費等值。</p>
</div><p>While the transition improved product quality, diversified distribution and strengthened margins, analysts say it also capped aggressive volume growth, pushing investors to reassess the company more as a steady profitability compounder rather than a high-growth insurance franchise.</p>
<div class="lb-trans"><p>雖然這一轉型提高了產品質量，分散了分銷渠道並增強了利潤率，但分析師表示，這也限制了激進的銷量增長，迫使投資者重新評估該公司，更像是一個穩定的盈利複合體，而不是一個高增長的保險品牌。</p>
</div><p>Recent earnings reinforced that perception. Management refrained from giving aggressive growth guidance for FY27 and instead emphasised protection-led growth, margin expansion and cost efficiency amid a volatile macro backdrop. Annual premium equivalent growth remained modest, though value of new business margins improved sharply due to a better product mix.</p>
<div class="lb-trans"><p>最近的財報強化了這種看法。管理層未對 2027 財年的激進增長指引做出承諾，而是強調了以保護為主導的增長、利潤率擴張和在動盪的宏觀背景下的成本效率。儘管年保費等值增長仍然温和，但由於產品組合的改善，新業務利潤率大幅提升。</p>
</div><p>The result is a stock that now trades at one of the lowest valuation multiples among large listed insurers. ICICI Prudential Life trades at around 1.3-1.5 times FY27 embedded value, below peers such as HDFC Life Insurance and SBI Life Insurance.</p>
<div class="lb-trans"><p>結果是，該股票現在的估值倍數在大型上市保險公司中處於最低水平之一。ICICI 保誠人壽的交易價格約為 2027 財年內嵌價值的 1.3-1.5 倍，低於 HDFC 人壽保險和 SBI 人壽保險等同行。</p>
</div><p>For bulls, that discount alongside strong solvency, improving protection mix and resilient profitability offers a potential floor for valuations. For bears, the Prudential stake-sale overhang, slower growth profile and muted distribution momentum raise questions about whether a meaningful rerating is possible in the near term.</p>
<div class="lb-trans"><p>對於看漲者來説，這一折扣加上強勁的償付能力、改善的保護組合和穩定的盈利能力為估值提供了潛在的底線。對於看跌者來説，保誠的股份出售壓力、較慢的增長特徵和低迷的分銷勢頭引發了對近期是否可能實現有意義的重新評級的質疑。</p>
</div>

Prudential’s Bharti Life Bet Triggers Fresh Overhang Fears for ICICI Pru Life

Money Control

摩根士丹利

Nomura Holdings, Inc.

野村控股

保誠

MORGAN STANLEY DEP SHS EA REP 1/1000 SHS NON CUM PFD O

MORGAN STANLEY DEP SHS REPSTG 1/1000TH PFD SER Q

MORGAN STANLEY DEP SHS REPS 1/1000 7.125% PFD E

MORGAN STANLEY NON-CUM DEP SH REP 1/1000 PFD SER I

MORGAN STANLEY 4.875 DEP SHS REP 1/1000 NCUM PFD SR L

MORGAN STANLEY 6.5%DEP SHS REPSTG 1/1000 NON CUM SER P

MORGAN STANLEY DEP SHS REPS 1/1000 PFD SER 'A'

MORGAN STANLEY DEP SHS REPR 1/1000TH INT PFD SER 'F' FX

MORGAN STANLEY DEP SHS REP 1/1000 NON-CUM PFD STK SER K

Macquarie Energy Transition ETF

保誠集團對 Bharti Life 的投資引發了對 ICICI Pru Life 的新一輪擔憂